Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17283405 | 0.92 | MAPK1 (0.43) | MAPK1ALDH1A1B4GALT1LGALS8LGALS3 | |
| SCHEMBL17283402 | 0.92 | MAPK1 (0.37) | MAPK1ALDH1A1B4GALT1LGALS8LGALS3 | |
| SCHEMBL17283403 | 0.88 | MAPK1 (0.34) | MAPK1ALDH1A1B4GALT1LGALS8LGALS3 | |
| SCHEMBL19700592 | 0.88 | BDNF (0.36) | MAPK1ALDH1A1B4GALT1LGALS8LGALS3 | |
| SCHEMBL19700593 | 0.87 | ALDH1A1 (0.34) | MAPK1ALDH1A1B4GALT1LGALS8LGALS3 | |
| SCHEMBL18875834 | 0.82 | TGM2 (0.40) | MAPK1CA1CA2 | |
| SCHEMBL18875796 | 0.75 | MAPK1 (0.41) | MAPK1LGALS8LGALS3LGALS4 | |
| SCHEMBL17283424 | 0.74 | MAPK1 (0.41) | MAPK1LGALS8LGALS3LGALS4 | |
| SCHEMBL17283437 | 0.74 | MAPK1 (0.42) | MAPK1B4GALT1LGALS8LGALS3LGALS4 | |
| SCHEMBL18503709 | 0.74 | LMNA (0.49) | MAPK1ALDH1A1B4GALT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | MAPK1 3820/4885ALDH1A1 974/4885B4GALT1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.